Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Chief Administrative Officer | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Pacira BioSciences, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 167,062 |
Ending reported balance
After 2026-06-04 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-03 · Tax withholding · Disposed 8,528 · Balance 177,321 F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award. Row 2 · 2026-06-04 · Sale · Disposed 10,259 · Balance 167,062 F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the issuer to cover tax withholding obligations upon vesting of a restricted stock unit award.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The Rule 10b5-1 trading plan was adopted on September 10, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 18, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,375 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · derivative · entry 9 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,375 shares Expires 2027-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 400 | $66.14 | $26,456.00 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 6 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,268 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.07 to $66.27, inclusive. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 23,040 | $65.24 | $1,503,129.60 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 5 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,668 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.02 to $65.95, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 4. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 13,127 | $47.65 | $625,501.55 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 4 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 6,338 | $43.54 | $275,956.52 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,600 | $38.35 | $99,710.00 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,243 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:24 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 1,375 | $44.20 | $60,775.00 |
DisclosureSEC source: 0001209191-22-004202 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,643 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 00:38 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 847 | $60.57 | $51,302.79 |
DisclosureSEC source: 0001209191-21-040090 · doc4.xml · nonDerivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,268 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.20 to $60.92, inclusive. Read SEC document |
| June 10, 2021 Filed Jun 12, 2021 00:38 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 4,842 | $59.43 | $287,760.06 |
DisclosureSEC source: 0001209191-21-040090 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,115 F2 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.03 to $59.99, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:38 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $60.96 | $0.00 |
DisclosureSEC source: 0001209191-21-040090 · doc4.xml · derivative · entry 4 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2031-06-09 F5 · derivative.exercise_date: The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| June 09, 2021 Filed Jun 12, 2021 00:38 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 7,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040090 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,957 F1 · shares: Represents restricted stock units that vest in four equal annual installments beginning on June 3, 2022, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:20 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,930 | $61.04 | $239,875.41 |
DisclosureSEC source: 0001209191-21-038901 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,957 F1 · shares: Represents shares sold by the reporting person to cover tax obligations upon the vesting of restricted stock units. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,339 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-21-026889 · doc4.xml · derivative · entry 10 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,010 Underlying: Common Stock · 6,339 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,859 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-21-026889 · doc4.xml · derivative · entry 9 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,765 Underlying: Common Stock · 8,859 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,125 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-21-026889 · doc4.xml · derivative · entry 8 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,375 Underlying: Common Stock · 4,125 shares Expires 2027-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $32.35 | $0.00 |
DisclosureSEC source: 0001209191-21-026889 · doc4.xml · derivative · entry 7 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,500 shares Expires 2026-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 7,030 | $68.11 | $478,813.30 |
DisclosureSEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 6 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,887 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.96 to $68.41, inclusive. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 14,793 | $66.40 | $982,255.20 |
DisclosureSEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 5 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,917 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.96 to $67.95, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 6,339 | $43.54 | $276,000.06 |
DisclosureSEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 4 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,710 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 8,859 | $38.35 | $339,742.65 |
DisclosureSEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 3 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,371 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 4,125 | $44.20 | $182,325.00 |
DisclosureSEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 2 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,512 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| April 13, 2021 Filed Apr 16, 2021 00:35 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,500 | $32.35 | $80,875.00 |
DisclosureSEC source: 0001209191-21-026889 · doc4.xml · nonDerivative · entry 1 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,387 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,819 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 36 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,349 Underlying: Common Stock · 2,819 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,878 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 35 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,624 Underlying: Common Stock · 7,878 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,502 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 34 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,500 Underlying: Common Stock · 5,502 shares Expires 2027-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,836 | $0.00 Strike: $32.35 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 33 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 5,836 shares Expires 2026-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,836 | $0.00 Strike: $40.34 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 32 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,836 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 3,200 | $60.22 | $192,704.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 21 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,887 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.130 to $60.370, inclusive. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 24,671 | $59.77 | $1,474,585.67 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 20 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,087 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.130 to $60.120, inclusive. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,819 | $43.54 | $122,739.26 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 19 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,758 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,878 | $38.35 | $302,121.30 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 18 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,502 | $44.20 | $243,188.40 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 17 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,836 | $32.35 | $188,794.60 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 16 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,559 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 17, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,836 | $40.34 | $235,424.24 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 15 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,816 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 31 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,168 Underlying: Common Stock · 2,816 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,874 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 30 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,502 Underlying: Common Stock · 7,874 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,499 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 29 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,002 Underlying: Common Stock · 5,499 shares Expires 2027-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,832 | $0.00 Strike: $32.35 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 28 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,336 Underlying: Common Stock · 5,832 shares Expires 2026-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,832 | $0.00 Strike: $40.34 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 27 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,836 Underlying: Common Stock · 5,832 shares Expires 2026-06-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 21,244 | $60.33 | $1,281,650.52 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 14 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,887 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.005 to $60.915, inclusive. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | SaleCommon Stock | 6,609 | $59.54 | $393,499.86 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 13 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,131 F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.990 to $59.980, inclusive. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 2,816 | $43.54 | $122,608.64 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 12 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,740 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,874 | $38.35 | $301,967.90 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 11 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,499 | $44.20 | $243,055.80 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 10 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,832 | $32.35 | $188,665.20 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 9 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,832 | $40.34 | $235,262.88 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · nonDerivative · entry 8 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,719 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,816 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 26 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,984 Underlying: Common Stock · 2,816 shares Expires 2029-06-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,874 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 25 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,376 Underlying: Common Stock · 7,874 shares Expires 2028-06-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,499 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 24 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,501 Underlying: Common Stock · 5,499 shares Expires 2027-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 23:13 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,832 | $0.00 Strike: $32.35 | $0.00 |
DisclosureSEC source: 0001209191-20-051037 · doc4.xml · derivative · entry 23 Williams Kristen Marie · CIK 0001296965 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,168 Underlying: Common Stock · 5,832 shares Expires 2026-12-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.